相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo
Ronit Mazor et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2017)
Immunogenicity of therapeutic recombinant immunotoxins
Ronit Mazor et al.
IMMUNOLOGICAL REVIEWS (2016)
Advances in Anticancer Immunotoxin Therapy
Christine Alewine et al.
ONCOLOGIST (2015)
Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results
Emily Mason-Osann et al.
SCIENTIFIC REPORTS (2015)
In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer
Kevin Hollevoet et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers
Christine Alewine et al.
MOLECULAR CANCER THERAPEUTICS (2014)
An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies
Tapan K. Bera et al.
LEUKEMIA RESEARCH (2014)
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes
Ronit Mazor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity
John E. Weldon et al.
MOLECULAR CANCER THERAPEUTICS (2013)
A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface
Zhewei Tang et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Influence of tumour micro-environment heterogeneity on therapeutic response
Melissa R. Junttila et al.
NATURE (2013)
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
Raffit Hassan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Hypoxia enhances cancer cell invasion through relocalization of the proprotein convertase furin from the trans-golgi network to the cell surface
Dominique Arsenault et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2012)
Strategies for extended serum half-life of protein therapeutics
Roland E. Kontermann
CURRENT OPINION IN BIOTECHNOLOGY (2011)
A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer
John E. Weldon et al.
FEBS JOURNAL (2011)
A novel high-affinity human monoclonal antibody to mesothelin
Mitchell Ho et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
RosettaRemodel: A Generalized Framework for Flexible Backbone Protein Design
Po-Ssu Huang et al.
PLOS ONE (2011)
A Recombinant Immunotoxin Targeting CD22 With Low Immunogenicity, Low Nonspecific Toxicity, and High Antitumor Activity in Mice
Johanna K. Hansen et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Aprotease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
John E. Weldon et al.
BLOOD (2009)
Pseudomonas exotoxin A: From virulence factor to anti-cancer agent
Philipp Wolf et al.
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY (2009)
The tumour microenvironment as a target for chemoprevention
Adriana Albini et al.
NATURE REVIEWS CANCER (2007)
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients
Masanori Onda et al.
JOURNAL OF IMMUNOLOGY (2006)
New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting,Western blotting, and ELISA
M Onda et al.
CLINICAL CANCER RESEARCH (2005)
Furin at the cutting edge: From protein traffic to embryogenesis and disease
G Thomas
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
Elevated furin expression in aggressive human head and neck tumors and tumors cell lines
DE Bassi et al.
MOLECULAR CARCINOGENESIS (2001)
分享论文
